Biogen Idec 1Q10 1Q Revenues: $1.1 billion (+7%) 1Q Earnings: $220 million (-11%) Comments: Tysabri sales rose 32% to $219 million in the quarter, while Avonex sales were up 7% to $593 million. Rituxan revenues dropped 9% to $255 million. BI wrote down $14 million from its investment in AVEO Pharmaceuticals, and another $13 million in expanded Medicaid rebates....